BACKGROUND: In patients with schizophrenia, the smoking cessation rate is low and the burden of smoking-related morbidity and mortality is high. Identification of factors associated with abstinence may allow clinicians to optimize treatment prior to a smoking cessation attempt. METHOD: To identify factors associated with successful smoking cessation in patients with a DSM-IV diagnosis of schizophrenia, we analyzed baseline data from 114 stable outpatient smokers with schizophrenia who participated in 1 of 2 smoking cessation trials. The outcome of interest was 4 weeks' continuous abstinence at the end of a 12-week nicotine dependence treatment intervention. Baseline factors associated with abstinence were identified with univariate methods and entered into a manual, forward-selection multivariable regression model to identify independent predictors of abstinence. The study was conducted from March 1999 to February 2004. RESULTS: Fourteen of 114 participants (12%) had biochemically verified 4 weeks' continuous abstinence at week 12. We included 10 noncorrelated variables with a univariate association with abstinence in a multivariable model, controlling for pharmacotherapy, age, and gender. Age at initiation of smoking and baseline variability in attentiveness, as measured by Continuous Performance Test-AX (CPT-AX) hit reaction time standard error, were independently associated with abstinence. For every year increase in age at initiation of smoking, the OR for abstinence was 1.36 (95% CI = 1.01 to 1.83), p = .048. For every millisecond decrease in the variability of the reaction time of CPT-AX, the OR for achieving abstinence was 1.55 (95% CI = 1.07 to 2.24), p = .021. CONCLUSION: Later initiation of smoking was associated with increased and baseline attentional impairment with reduced odds of abstinence. Additional research to further our understanding of the relationship between attentional impairment and cigarette smoking in schizophrenia may lead to improved nicotine dependence treatments for this group. Copyright 2008 Physicians Postgraduate Press, Inc.
BACKGROUND: In patients with schizophrenia, the smoking cessation rate is low and the burden of smoking-related morbidity and mortality is high. Identification of factors associated with abstinence may allow clinicians to optimize treatment prior to a smoking cessation attempt. METHOD: To identify factors associated with successful smoking cessation in patients with a DSM-IV diagnosis of schizophrenia, we analyzed baseline data from 114 stable outpatient smokers with schizophrenia who participated in 1 of 2 smoking cessation trials. The outcome of interest was 4 weeks' continuous abstinence at the end of a 12-week nicotine dependence treatment intervention. Baseline factors associated with abstinence were identified with univariate methods and entered into a manual, forward-selection multivariable regression model to identify independent predictors of abstinence. The study was conducted from March 1999 to February 2004. RESULTS: Fourteen of 114 participants (12%) had biochemically verified 4 weeks' continuous abstinence at week 12. We included 10 noncorrelated variables with a univariate association with abstinence in a multivariable model, controlling for pharmacotherapy, age, and gender. Age at initiation of smoking and baseline variability in attentiveness, as measured by Continuous Performance Test-AX (CPT-AX) hit reaction time standard error, were independently associated with abstinence. For every year increase in age at initiation of smoking, the OR for abstinence was 1.36 (95% CI = 1.01 to 1.83), p = .048. For every millisecond decrease in the variability of the reaction time of CPT-AX, the OR for achieving abstinence was 1.55 (95% CI = 1.07 to 2.24), p = .021. CONCLUSION: Later initiation of smoking was associated with increased and baseline attentional impairment with reduced odds of abstinence. Additional research to further our understanding of the relationship between attentional impairment and cigarette smoking in schizophrenia may lead to improved nicotine dependence treatments for this group. Copyright 2008 Physicians Postgraduate Press, Inc.
Authors: Tony P George; Jennifer C Vessicchio; Angelo Termine; Thomas A Bregartner; Alan Feingold; Bruce J Rounsaville; Thomas R Kosten Journal: Biol Psychiatry Date: 2002-07-01 Impact factor: 13.382
Authors: Richard D Hurt; Troy D Wolter; Nancy Rigotti; J Taylor Hays; Raymond Niaura; Michael J Durcan; David Gonzales; David P L Sachs; J Andrew Johnston; Kenneth P Offord Journal: Addict Behav Date: 2002 Jul-Aug Impact factor: 3.913
Authors: K K Higa; A Grim; M E Kamenski; J van Enkhuizen; X Zhou; K Li; J C Naviaux; L Wang; R K Naviaux; M A Geyer; A Markou; J W Young Journal: Psychopharmacology (Berl) Date: 2017-02-28 Impact factor: 4.530
Authors: Sungwon Roh; Susanne S Hoeppner; David Schoenfeld; Catherine A Fullerton; Luke E Stoeckel; A Eden Evins Journal: Psychopharmacology (Berl) Date: 2013-10-11 Impact factor: 4.530
Authors: Joelle C Ferron; Timothy Devitt; Gregory J McHugo; Jessica A Jonikas; Judith A Cook; Mary F Brunette Journal: Community Ment Health J Date: 2016-03-01
Authors: Randi M Schuster; Corinne Cather; Gladys N Pachas; Haiyue Zhang; Kristina M Cieslak; Susanne S Hoeppner; David Schoenfeld; A Eden Evins Journal: Addict Behav Date: 2017-02-24 Impact factor: 3.913
Authors: Rebecca L Ashare; Jeffrey N Valdez; Kosha Ruparel; Benjamin Albelda; Ryan D Hopson; John R Keefe; James Loughead; Caryn Lerman Journal: Psychopharmacology (Berl) Date: 2013-07-05 Impact factor: 4.530
Authors: Gladys N Pachas; Corinne Cather; Sarah A Pratt; Bettina Hoeppner; Johanna Nino; Sara V Carlini; Eric D Achtyes; Harry Lando; Kim T Mueser; Nancy A Rigotti; Donald C Goff; A Eden Evins Journal: J Dual Diagn Date: 2012-05-11
Authors: Freda Patterson; Christopher Jepson; James Loughead; Kenneth Perkins; Andrew A Strasser; Steven Siegel; Joseph Frey; Ruben Gur; Caryn Lerman Journal: Drug Alcohol Depend Date: 2009-09-05 Impact factor: 4.492